Objectives: The purpose of our study was to describe our preliminary experience of evaluating mediastinal lymph node metastases with diffusion-weighted magnetic resonance (MR) imaging in patients with non-small cell lung cancer.
T he recent development of echo-planar magnetic resonance (MR) imaging techniques and parallel imaging techniques such as sensitivity encoding (SENSE) has made possible the acquisition of diffusion-weighted MR imaging (DWI) of the body. Takahara et al 1 reported that high resolution DWI with the short inversion time inversion recovery-echo planar imaging (STIR-EPI) sequence and free-breathing scanning can be used to create optimum 3-dimensional display of the whole body and suggested the potential capability of DWI as a novel tool for evaluating malignancy. In recent studies, DWI has been applied to the head and neck, liver, pancreas, breast, prostate, and colon for differentiation between benign and malignant lesions. [2] [3] [4] [5] [6] [7] [8] DWI has also recently been applied to characterize lung carcinomas, 9 but its role in the evaluation of mediastinal lymph node has yet to be determined. As patients with N2 mediastinal lymph node metastases may benefit from surgical resection in combination with neoadjuvant therapy protocols and radiation therapy, identification of mediastinal lymph node metastasis with preoperative diagnostic imaging has become particularly important in non-small cell lung cancer (NSCLC). 10 Computed tomography (CT) has been used as the primary diagnostic imaging modality for evaluation of mediastinal lymph node metastasis in patients with primary lung cancer. [11] [12] [13] [14] [15] [16] [17] [18] Conventional staging with mediastinoscopy is the most accurate means of staging; however, it is associated with a small, but considerable, morbidity and mortality. 19 Recently, F-18-deoxyglucose (FDG)-positron emission tomography (PET) and integrated FDG-PET/CT have been introduced and studies to date show that FDG-PET is superior to CT in the assessment of mediastinal nodal metastases. [20] [21] [22] [23] [24] [25] [26] [27] [28] Although recent studies reported that STIR MR imaging enabled differentiation of lymph nodes with metastasis from those without in NSCLC, 29, 30 clinical studies to assess the usefulness of DWI for detecting mediastinal lymph node metastasis in patients with NSCLC have not been reported. We hypothesized that DWI could be useful for evaluating mediastinal lymph nodes in patients with NSCLC because it detects abnormalities on the basis of tumor cellularity in addition to findings obtained with conventional MR imaging. 31 Therefore, the purpose of our study is to describe our preliminary experience of evaluating mediastinal lymph node metastases with this method in patients with NSCLC.
MATERIALS AND METHODS

Patients
Our institutional review board approved this prospective study. Informed consent was obtained from all patients for MR imaging examination. Inclusion criteria included all patients with histopathologically proved NSCLC who were referred to the Department of Surgery for evaluation of operability from December 2005 to December 2006. Exclusion criteria include patients who did not undergo mediastinal lymph node dissection or sampling owing to poor cardiac or pulmonary reserve. None of the patients refused the MRI. During the time of the study period, a total of 44 consecutive patients were screened, but 2 patients were excluded on the basis of poor cardiac or pulmonary reserve. Forty-two patients thus comprised our final study population (30 men, 12 women, aged 41 to 83 y, mean 66 y). As detailed in the following section, each of these 42 patients underwent MR imaging for preoperative assessment with mean duration between MR study and surgery of 6.6 days (range: 1 to 20 d).
MR Imaging Examination
All patients underwent MR imaging with a 1.5 T Intera Achieva (Philips Medical Systems, Best, The Netherlands) scanner. Transverse STIR-EPI diffusionweighted MR images, a technique originally reported by Takahara et al, 1 were obtained by using SENSE body coil [field of view, 420 mm; rectangular field of view, 70%; number of slices, 60; scan percentage, 78%; half scan factor, 0.6; EPI factor, 47; SENSE factor, 8; slice thickness, 5 mm; slice gap, À 0.4 mm (overlap); matrix, 128; b-factor, 1000 s/mm 2 ; motion probing gradient, 3 axis; repetition time (TR), 5037 ms; echo time (TE), 68 ms; inversion time (TI), 180 ms; acquisition time, 343 s]. Transverse electrocardiographically and respiratory-triggered T2-weighted images were also obtained in all patients (field of view, 350 mm; rectangular field of view, 80%; number of slices, 25 to 32; turbo factor, 19; SENSE factor, 1.5; slice thickness, 7 mm; slice gap, 0.7 mm; matrix, 320; TR, 1 to 2 R-R interval; TE, 110 ms; number of signals acquired, 2; acquisition time, 300 to 420 s, depending on heart rate and respiratory rate).
Image Analysis
The studies were interpreted on an imaging work station (View Forum version 4.1; Philips Medical Systems, Best, The Netherlands). All cases were interpreted blinded to all surgical results by a thoracic radiologist with more than ten years clinical experience interpreting thoracic MR examinations. Images were reviewed using combined cine stack with static oneon-one viewing. All DWI were displayed in standard window settings (window level 30 to 40, window width 150 to 450) using inverted gray scale. Because the resolution of STIR-EPI DWI is limited for depicting anatomic landmarks, T2-weighted images were reviewed in conjunction with DWI to identify the location of lymph nodes. After review of the transverse DWI and T2-weighted images, when we needed to register the DWI to the T2-weighted image so that the two images were brought into anatomic correspondence, multiplanar image reformats were obtained as this DWI technique allows multiplanar image reformats for anatomic localization. On DWI, a mediastinal lymph node metastasis was defined as a focus of low signal intensity at the site of a visible lymph node on corresponding T2-weighted image regardless of its size. 1 
Surgical and Histopathologic Analysis
Lobectomy or pneumonectomy with complete standard ipsilateral hilar and mediastinal lymph node dissection or sampling was performed on the basis of the surgical findings in all patients by two thoracic surgeons each with more than ten years experience in operating lung cancer patients. The surgeons labeled resected lymph nodes by numbering them according to lymph node map by Mountain and Dresler. 32 All resected nodes were fixed in 10% formalin and embedded in paraffin. Specimens were stained with hematoxylin-eosin and then examined with light microscopy by a pathologist with more than twenty years experience.
Statistical Analysis
The sensitivity, specificity, accuracy, and positive and negative predictive values for detecting mediastinal lymph node metastases were calculated.
RESULTS
The nodal stages in 42 patients included N0 in 34 (81%) patients, N1 in 3 (7%) and N2 in 5 (12%). DWI accurately identified N0 status in 31 (91%) of 34 patients, N1 disease in 2 (67%) of 3 patients, and N2 disease in 4 (80%) of 5 patients (Fig. 1) . The nodal stages were incorrectly diagnosed in 2 patients with pathologic N0 disease as N1, and in 1 patient with pathologic N1 disease as N0. Additionally, 1 patient with pathologic N2 disease was understaged as N1, and 1 patient with pathologic N0 disease was overstaged as N2. In the latter case, an inflammatory lymph node mimicked a metastatic lymph node on DWI (Fig. 2) .
As the purpose of this study is to describe our preliminary experience of evaluating mediastinal lymph node metastasis, that is, N2 disease, in patients who are surgical candidates for treatment of NSCLC, one false positive and 1 false negative interpretation occurred. Thus, 40 (95%) of 42 patients were accurately diagnosed for N2 disease by DWI MR. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of DWI for N2 mediastinal lymph node metastasis were 80%, 97%, 80%, 97%, and 95%, respectively (Table 1) .
DISCUSSION
Accurate preoperative staging of NSCLC is increasingly important as patients with N2 mediastinal lymph node metastases may benefit from surgical resection in combination with neoadjuvant chemotherapy and radiation therapy. 10 Importantly, our preliminary experience with DWI demonstrates a high negative predictive value of 97% for excluding mediastinal lymph node metastasis from NSCLC.
A variety of non-invasive methods are available for assessing intrathoracic nodal status in patients with NSCLC. Currently, FDG-PET is the most accurate method for preoperative staging of lymph node metastasis [20] [21] [22] [23] [24] [25] [26] [27] [28] These methods are limited by relying upon size criteria for assessment of mediastinal lymph node metastasis, with unacceptable sensitivity and specificity using this criterion. Previous reports have compared the accuracy of traditional MRI and CT in the evaluation of hilar and mediastinal adenopathy. [11] [12] [13] [14] [33] [34] [35] The sensitivity and specificity of MR imaging have been reported to be similar to those of CT scanning in identifying mediastinal lymph node metastases. [33] [34] [35] Recent studies reported that STIR MR imaging enabled differentiation of lymph nodes with metastasis from those without metastases. 29, 30 To our knowledge, however, the accuracy of DWI for assessing mediastinal lymph nodes has not been reported before this study.
DWI detects abnormalities on the basis of tumor cellularity. Tumors are more cellular than the tissue from which they originate and thus seem to be of relatively high signal intensity at DWI. 31 Lyng et al 36 reported an increased metastatic capacity of tumors with high cellularity. The sensitivity and specificity of DWI for detecting mediastinal lymph node metastasis in our study were superior to those of previous reports using CT (50% to 95%, 44% to 94%, respectively) [11] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] [26] [27] [28] and similar to FDG-PET or integrated PET/CT (73% to 92%, 81% to 100%, respectively). [20] [21] [22] [23] [24] [25] [26] [27] [28] In general, however, a lack of specificity limits all non-invasive imaging modalities. Even FDG-PET is limited in this regard. [24] [25] [26] For example, Liewald et al 25 have concluded that FDG uptake of mediastinal lymph nodes at PET should not be interpreted as proof of malignancy. In our study, 1 patient with N2 disease was understaged and 1 patient with histologic evidence of reactive lymphoid hyperplasia because of concurrent pneumonia was overstaged by DWI. It is difficult to determine the cause of adenopathy as most studies have previously reported. 35 In addition, it should be noted that microscopic metastases might be overlooked at conventional histopathologic examination, as demonstrated with the addition of immunohistochemical staining or polymerase chain reaction techniques. [37] [38] [39] [40] There are several potential advantages of DWI for imaging patients with NSCLC. First, DWI does not require the administration of contrast medium; thus, this procedure can be applied to patients with renal disease who may not be able to undergo contrast-enhanced CT or MR studies. Second, this sequence can be incorporated into standard imaging protocols without a significant increase in the examination time. Third, DWI of mediastinal lymph nodes could be combined with DWI and apparent diffusion coefficient (ADC) characterization of primary lung cancer, another promising new area of investigation. 9 Finally, although we have not compared it to PET, we anticipate that this method could potentially be used in settings where PET is less available than MR.
Our preliminary results suggest that DWI may have the potential to play a role in evaluating mediastinal lymph node metastases from NSCLC in the preoperative setting. However, before it is introduced into the clinical setting, several limitations should first be addressed in future studies. First, we did not perform a comparative study with FDG-PET or integrated FDG-PET/CT, and our study population was comprised of a large percentage (81%) of patients with N0 disease, with a relatively limited number of patients with N2 disease. Therefore, a prospective study employing both FDG-PET and DWI in larger population would be useful to determine the efficacy of DWI. Second, we did not evaluate the ADC value of lymph nodes. Most of the mediastinal lymph nodes detected in our MR study were relatively small in size and it was difficult to measure the ADC values of these nodes for this reason. For example, Wang et al, 2 have reported that image distortions along the phaseencoding direction were unavoidable and the ADC values measured in small lesions might be inaccurate. Third, MR images were interpreted by one thoracic radiologist in our study. Independent assessment of MR imaging by multiple radiologists would be helpful to determine diagnostic accuracy among different observers and to assess for interobserver agreement.
In conclusion, our preliminary results show that DWI has a high negative predictive value for excluding mediastinal lymph node metastases from NSCLC and has the potential to serve as a viable alternative imaging method for the preoperative staging of mediastinal lymph node in patients with NSCLC. Although promising, further studies are necessary to determine the accuracy of this technique in a larger cohort of patients with comparison to PET. 
